News | Proton Therapy | April 09, 2019

Varian Discloses First Preclinical Results of Flash Therapy in Cancer Treatment

First preclinical results with ultra-high-dose proton therapy presented at AACR

Varian Discloses First Preclinical Results of Flash Therapy in Cancer Treatment

April 9, 2019 — Varian, in partnership with the University of Maryland School of Medicine’s Department of Radiation Oncology and the Maryland Proton Treatment Center, presented publicly the first pre-clinical results of its research on ultra-high-dose rate cancer treatments with protons. Known as Flash therapy, it is a non-invasive therapy for cancer delivering high doses of radiation in ultra-high-speeds (less than 1 second) and represents the potential for a major breakthrough in the treatment of cancer. The preclinical Flash therapy results — presented at the American Association for Cancer Research (AACR) annual meeting, March 29-April 3 in Atlanta — showed reduced toxicity in healthy tissues and organs.

Conducted on a clinical device capable of translation to humans, the Flash therapy preclinical tests, compared to conventional proton treatments, displayed 25-30 percent less damage to lung tissue, resulting in less fibrosis of the lung, and an average of 35 percent reduction in skin dermatitis during treatment.

The FlashForward Consortium, comprised of 14 cancer centers, is focused on preclinical research, clinical implementation and advocacy efforts of Flash therapy. Working groups in the FlashForward Consortium are identifying preclinical study design for understanding this therapy, developing and sharing protocols that will enable a safe and quality clinical start for new users, and assist with regulatory and advocacy efforts.

“Partnering with Varian’s Global Translational Science team on the first proton Flash pre-clinical study, and being one of the founding members of the FlashForward Consortium, is a significant step in building a foundation of research and bridging the gap to patient benefits in this potentially game-changing therapy,” said William F. Regine, M.D., The Isadore & Fannie Foxman Chair and professor, Department of Radiation Oncology at the University of Maryland School of Medicine, and executive director of the Maryland Proton Treatment Center. The pre-clinical study was led by Zeljko Vujaskovic, M.D., Ph.D., professor of radiation oncology and director of the Division of Translational Radiation Services, and Lauren Jackson, Ph.D., associate professor of radiation oncology and deputy director of translational radiation sciences.

Read more about the data presented at AACR here.

For more information: www.varian.com

Related Content

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Radiation Therapy | May 10, 2019
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve